Chevy Chase Trust Holdings LLC Trims Position in Becton, Dickinson and Company (NYSE:BDX)

Chevy Chase Trust Holdings LLC trimmed its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 176,190 shares of the medical instruments supplier’s stock after selling 2,332 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.06% of Becton, Dickinson and Company worth $43,598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Advisors Asset Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 96.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 2,604 shares of the medical instruments supplier’s stock worth $673,000 after buying an additional 1,278 shares during the period. First Foundation Advisors grew its holdings in Becton, Dickinson and Company by 11.1% during the 3rd quarter. First Foundation Advisors now owns 1,390 shares of the medical instruments supplier’s stock worth $359,000 after acquiring an additional 139 shares in the last quarter. Belpointe Asset Management LLC increased its position in Becton, Dickinson and Company by 42.1% during the 3rd quarter. Belpointe Asset Management LLC now owns 1,989 shares of the medical instruments supplier’s stock valued at $514,000 after purchasing an additional 589 shares during the period. Harbour Investments Inc. raised its holdings in shares of Becton, Dickinson and Company by 7.4% in the 3rd quarter. Harbour Investments Inc. now owns 1,429 shares of the medical instruments supplier’s stock valued at $369,000 after purchasing an additional 98 shares in the last quarter. Finally, Revisor Wealth Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $320,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded up $2.96 during mid-day trading on Wednesday, reaching $224.43. 1,390,866 shares of the company traded hands, compared to its average volume of 1,426,929. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $287.32. The firm’s fifty day moving average is $233.54 and its two-hundred day moving average is $237.20. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The company has a market capitalization of $64.86 billion, a price-to-earnings ratio of 49.80, a price-to-earnings-growth ratio of 1.97 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.86 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.69%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Roland Goette sold 3,300 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total value of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Roland Goette sold 3,300 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $236.70, for a total transaction of $781,110.00. Following the sale, the executive vice president now directly owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders have sold 8,615 shares of company stock worth $2,033,381 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on BDX shares. The Goldman Sachs Group initiated coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a “buy” rating and a $274.00 price objective on the stock. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. Evercore ISI cut their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Barclays boosted their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $280.86.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.